Tiansheng Pharmaceutical Group Co Ltd (002872) - Net Assets
Based on the latest financial reports, Tiansheng Pharmaceutical Group Co Ltd (002872) has net assets worth CN¥1.97 Billion CNY (≈ $288.25 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.65 Billion ≈ $387.63 Million USD) and total liabilities (CN¥679.17 Million ≈ $99.38 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tiansheng Pharmaceutical Group Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.97 Billion |
| % of Total Assets | 74.36% |
| Annual Growth Rate | 6.45% |
| 5-Year Change | -15.71% |
| 10-Year Change | 23.66% |
| Growth Volatility | 23.05 |
Tiansheng Pharmaceutical Group Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Tiansheng Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002872 asset base for the complete picture of this company's asset base.
Annual Net Assets for Tiansheng Pharmaceutical Group Co Ltd (2012–2024)
The table below shows the annual net assets of Tiansheng Pharmaceutical Group Co Ltd from 2012 to 2024. For live valuation and market cap data, see market cap of Tiansheng Pharmaceutical Group Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.01 Billion ≈ $294.76 Million |
-3.88% |
| 2023-12-31 | CN¥2.10 Billion ≈ $306.66 Million |
-4.20% |
| 2022-12-31 | CN¥2.19 Billion ≈ $320.11 Million |
-4.02% |
| 2021-12-31 | CN¥2.28 Billion ≈ $333.52 Million |
-4.62% |
| 2020-12-31 | CN¥2.39 Billion ≈ $349.69 Million |
-19.11% |
| 2019-12-31 | CN¥2.95 Billion ≈ $432.30 Million |
-7.15% |
| 2018-12-31 | CN¥3.18 Billion ≈ $465.60 Million |
-0.23% |
| 2017-12-31 | CN¥3.19 Billion ≈ $466.69 Million |
+71.56% |
| 2016-12-31 | CN¥1.86 Billion ≈ $272.02 Million |
+14.12% |
| 2015-12-31 | CN¥1.63 Billion ≈ $238.37 Million |
+13.84% |
| 2014-12-31 | CN¥1.43 Billion ≈ $209.40 Million |
+32.78% |
| 2013-12-31 | CN¥1.08 Billion ≈ $157.71 Million |
+13.25% |
| 2012-12-31 | CN¥951.66 Million ≈ $139.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tiansheng Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥139.00 Million | 6.93% |
| Common Stock | CN¥318.00 Million | 15.85% |
| Other Comprehensive Income | CN¥147.90 Million | 7.37% |
| Other Components | CN¥1.40 Billion | 69.84% |
| Total Equity | CN¥2.01 Billion | 100.00% |
Tiansheng Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Tiansheng Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aldel Financial II Inc. Class A Ordinary Shares
NASDAQ:ALDF
|
$252.25 Million |
|
Humana AB (publ)
ST:HUM
|
$252.31 Million |
|
Te Chang Construction Co Ltd
TWO:5511
|
$252.32 Million |
|
AK Sigorta AS
IS:AKGRT
|
$252.37 Million |
|
Bioteque
TWO:4107
|
$252.17 Million |
|
SiS Distribution (Thailand) Public Company Limited
BK:SIS
|
$252.15 Million |
|
Chicago Atlantic Real Estate Finance Inc
NASDAQ:REFI
|
$252.12 Million |
|
So-Young International Inc
NASDAQ:SY
|
$252.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tiansheng Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,091,482,920 to 2,005,684,070, a change of -85,798,850 (-4.1%).
- Net loss of 87,403,826 reduced equity.
- Dividend payments of 15,258,140 reduced retained earnings.
- Other comprehensive income increased equity by 143,324,576.
- Other factors decreased equity by 126,461,460.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-87.40 Million | -4.36% |
| Dividends Paid | CN¥15.26 Million | -0.76% |
| Other Comprehensive Income | CN¥143.32 Million | +7.15% |
| Other Changes | CN¥-126.46 Million | -6.31% |
| Total Change | CN¥- | -4.10% |
Book Value vs Market Value Analysis
This analysis compares Tiansheng Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.18x to 0.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥4.59 | CN¥5.42 | x |
| 2013-12-31 | CN¥4.92 | CN¥5.42 | x |
| 2014-12-31 | CN¥6.36 | CN¥5.42 | x |
| 2015-12-31 | CN¥6.64 | CN¥5.42 | x |
| 2016-12-31 | CN¥7.56 | CN¥5.42 | x |
| 2017-12-31 | CN¥10.64 | CN¥5.42 | x |
| 2018-12-31 | CN¥12.58 | CN¥5.42 | x |
| 2019-12-31 | CN¥9.11 | CN¥5.42 | x |
| 2020-12-31 | CN¥7.36 | CN¥5.42 | x |
| 2021-12-31 | CN¥7.15 | CN¥5.42 | x |
| 2022-12-31 | CN¥6.86 | CN¥5.42 | x |
| 2023-12-31 | CN¥6.58 | CN¥5.42 | x |
| 2024-12-31 | CN¥6.31 | CN¥5.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tiansheng Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.34%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.36x
- Recent ROE (-4.36%) is below the historical average (1.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 11.91% | 10.95% | 0.58x | 1.89x | CN¥17.66 Million |
| 2013 | 12.06% | 8.86% | 0.66x | 2.07x | CN¥21.48 Million |
| 2014 | 11.85% | 9.89% | 0.67x | 1.80x | CN¥25.71 Million |
| 2015 | 12.14% | 10.42% | 0.64x | 1.81x | CN¥33.90 Million |
| 2016 | 12.43% | 10.76% | 0.62x | 1.88x | CN¥43.96 Million |
| 2017 | 7.93% | 10.99% | 0.46x | 1.58x | CN¥-64.73 Million |
| 2018 | 0.50% | 0.72% | 0.46x | 1.50x | CN¥-295.81 Million |
| 2019 | -7.56% | -13.05% | 0.38x | 1.52x | CN¥-508.67 Million |
| 2020 | -21.09% | -41.04% | 0.33x | 1.56x | CN¥-727.62 Million |
| 2021 | -3.18% | -9.82% | 0.24x | 1.37x | CN¥-299.68 Million |
| 2022 | -4.19% | -15.08% | 0.20x | 1.36x | CN¥-309.83 Million |
| 2023 | -4.45% | -16.07% | 0.21x | 1.34x | CN¥-302.22 Million |
| 2024 | -4.36% | -15.34% | 0.21x | 1.36x | CN¥-287.97 Million |
Industry Comparison
This section compares Tiansheng Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,109,695,154
- Average return on equity (ROE) among peers: 0.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tiansheng Pharmaceutical Group Co Ltd (002872) | CN¥1.97 Billion | 11.91% | 0.34x | $252.21 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $660.31 Million | 2.17% | 0.39x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About Tiansheng Pharmaceutical Group Co Ltd
Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, gynecological, orthopedic, cardiology, diabetes, anesthetic, and others. It also provides traditional Chinese medicines and glucose injection. The company was founded in… Read more